DOCSLIB.ORG

International Growth List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

! Preface Causes of Disrupons in Children’s Growth Scienfic Evidence Advancements in technology, clinical research, and high speed informa'on sharing have collec'vely facilitated the discovery of an unprecedented amount of informa'on pertaining to the gene'c causes of children’s growth failure, overgrowth or other growth irregulari'es. For decades, scien'sts have been mapping out the millions of human gene'c details in discovery. During this process they iden'fied diseases/syndromes which are apparent in a child who displays all of the characteris'cs (“classic” form) of that syndrome. Other children may have the same syndrome but in a “par'al” form. There are typically mul'ple varie'es of the par'al forms. It is a complicated discovery and cataloguing process which con'nues to this day. The varia'on of characteris'cs within each syndrome means that growth irregulari'es may be the result of a variety of mechanisms. As you will note in the categories within this document, some children have issues which are (non-syndromic) and do not yet have a “name” but have a list of characteris'cs of which growth is listed as a condi'on. Therefore, those “un-named” syndromes are listed in the Alphabe'cal list contained herein. What does this increase in knowledge do for families and growth affected children? Poten'ally, gene'c explana'ons can afford physicians an opportunity to iden'fy causes for growth failure or overgrowth at a much younger age. If treatments are available for the iden'fied medical cause, ini'a'ng therapies as soon as possible could change the child’s future and health for his/her en're life'me. Changing Public Misconcep'ons There are many assump'ons surrounding children’s growth. It is generally believed that if we “wait and see” … a child who is small will eventually catch up to his/her peers. The opposite side of growth issues pertains to a child who is excep'onally tall for his/her age, par'cularly if the child is male. Parents and other caregivers oTen consider overgrowth as a “benefit” rather than a health warning. As a major sign of health, a child’s growth paVern is NOT simply a cosme'c or appearance issue. Children’s growth should be checked annually and regarded with serious considera'on. NO irregular growth (too much or too lile) is safe for children if it is caused by a hidden medical issue. ICOSEP is a coali'on of pa'ent organiza'ons represen'ng various “growth” condi'ons. Governments, medical socie'es and others have endorsed and supported ICOSEP and our educa'onal ini'a've. We have one goal: to share a simple truth about children’s growth so that children throughout the country may be iden'fied with enough 'me to intervene for their best life'me of health. Join us! Each year, on September 20th, we share one message via our annual Children’s Growth Awareness educa'onal ini'a've. Materials are downloadable and free for this campaign use. Visit: hVp://icosep.org and click the Growth Awareness Day tab for more details. Table of Contents !2 Sec/on 1 Alphabe'zed list of Medical Condi'ons Impac'ng Children’s Growth Page 4-109 Sec/on 2 Itemized Summary Search Lists for: Decreased Serum IGF-1 Associated Diseases Page 109 IGF-1 Diseases Page 109 Dispropor'onate Short Limb Associated Diseases Page 110-115 Dispropor'onate Short Stature Diseases Page 116-122 Dispropor'onate Short Trunk Short Stature Page 122-123 Dysplasia’s Page 123-126 Propor'onate Short Stature Associated Diseases Page 125-130 Growth Hormone Deficiency Page 130-133 Growth Hormone Deficiency (Monarch search example) Page 133-138 Secondary Growth Hormone Deficiency Page 138-139 Pituitary Dwarfism Associated Diseases Page 139 Growth Hormone Excess Page 140 Precocious Puberty Page 141-150 Sec/on 3 Cross-referenced Master List with URL Informa'on and Notes Page 151-432 Sec/on 4 Alphabe'zed Resources Page 432-434 Legal No'ce Page 435 !3 Alphabe/zed List of Growth Impac/ng Diagnoses Contains all syndrome/condi'on names (including AkA names from the detailed list in Sec'on 3). 1 10q Duplicaon 2 10q Trisomy 3 12q Duplicaon 4 12q Trisomy 5 13q Dele'ons (various) Overview 6 14q Dele'ons Between 14q22 and 14q32 7 14q Dele'ons Proximal to 14q22 8 14q22q23 Microdele'on Syndrome 9 15q13.3 Microdele'on Syndrome 10 16p13.11 Microdele'on Syndrome 11 17p13.3 Microduplica'on Syndrome 12 17q Deleon 13 17q Monosomy 14 17q11 Microdele'on Syndrome 15 17q11.2 Microduplica'on Syndrome 16 18q Deleon Syndrome; Deleons from 18q11.2 to 18q21.2 17 19 XLMR 18 1p36 Deleon Syndrome 19 1q Duplicaon 20 1q Trisomy 21 1q21.1 Deleon Syndrome 22 1q21.1 Microdele'on 23 1q21.1 Microduplica'ons 24 1q24q25 Microdele'on Syndrome 25 1q41-q42 Deleon Syndrome 26 1q41-q42 Microdele'on Syndrome 27 1-Spondylometaphyseal Dysplasia - Sutcliffe Type 28 20p12.3 Microdele'on Syndrome 29 21q Deleon Syndrome !4 30 22q11.2 Deleon Syndrome 31 22q13 Microdele'on Syndrome 32 22q13.3 Deleon Syndrome 33 2-Spondylometaphyseal Dysplasia Axial 34 3C Syndrome 35 3M Syndrome 36 3MC Syndrome 37 3-Methylglutaconic Aciduria Type II 38 3p Deleon 39 3p Duplicaon 40 3p Monosomy 41 3p- Syndrome 42 3p Trisomy 43 3q26.33-3q28 Microdele'on 44 3-Spondylometaphyseal Dysplasia, Megarbane-Dagher-Melki Type 45 4 H Syndrome 46 4p Deleon 47 4p Monosomy 48 4q Dele'on Syndrome, Par'al 49 4q Monosomy 50 4q28.1 51 5p Monosomy 52 5p Par'al Monosomy Syndrome 53 5p Syndrome 54 5p13 Microduplica'on Syndrome 55 6-Spondylometaphyseal Dysplasia with Cone-Rod Dystrophy 56 8p Inverted Duplica'on/Dele'on Syndrome 57 8p- Syndrome, Par'al 58 8q Deleon 59 8q Monosomy 60 8q13 Microdele'on Syndrome 61 9p Par'al Monosomy !5 62 9p13.3-p13.
Recommended publications
  • Clinical and Genetic Characterisation of Hereditary Motor Neuropathies

    Clinical and Genetic Characterisation of Hereditary Motor Neuropathies

    Clinical and genetic characterisation of hereditary motor neuropathies Boglarka Bansagi Institute of Genetic Medicine January 2017 A Thesis submitted for the degree of Doctor of Philosophy at Newcastle University 'I dare do all that may become a man; who dares do more is none.' (Shakespeare) „Szívet vagy mundért cserélhet az is, ki házat, hazát holtig nem cserél, de hű maradhat idegenben is, kiben népe mostoha sorsa él.” (Tollas Tibor) Author’s declaration This Thesis is submitted to Newcastle University for the degree of Doctor of Philosophy at Newcastle University. I, Boglarka Bansagi, confirm that the work presented in this Thesis is my own. Where information has been derived from other sources, it has been indicated in the Thesis. I can confirm that none of the material offered in this Thesis has been previously submitted by me for a degree or qualification in this or any other university. Abstract Inherited peripheral neuropathies or Charcot-Marie-Tooth disease (CMT) are common neuromuscular conditions, characterised by distal motor atrophy and weakness with variable range of sensory impairment and classified according to demyelinating (CMT1) or axonal (CMT2) pathology. The number of genes causing CMT has rapidly increased due to improved genetic testing technology, even though gene identification has remained challenging in some subgroups of CMT. Hereditary motor neuropathies (HMN) encompass heterogeneous groups of disorders caused by motor axon and neuron pathology. The distal hereditary motor neuropathies (dHMN) are rare length-dependent conditions, which show significant clinical and genetic overlap with motor neuron diseases. Several (>30) causative genes have been identified for ~20% of dHMN patients, which predicts extreme genetic heterogeneity in this group.
  • Alport Syndrome of the European Dialysis Population Suffers from AS [26], and Simi- Lar Figures Have Been Found in Other Series

    Alport Syndrome of the European Dialysis Population Suffers from AS [26], and Simi- Lar Figures Have Been Found in Other Series

    DOCTOR OF MEDICAL SCIENCE Patients with AS constitute 2.3% (11/476) of the renal transplant population at the Mayo Clinic [24], and 1.3% of 1,000 consecutive kidney transplant patients from Sweden [25]. Approximately 0.56% Alport syndrome of the European dialysis population suffers from AS [26], and simi- lar figures have been found in other series. AS accounts for 18% of Molecular genetic aspects the patients undergoing dialysis or having received a kidney graft in 2003 in French Polynesia [27]. A common founder mutation was in Jens Michael Hertz this area. In Denmark, the percentage of patients with AS among all patients starting treatment for ESRD ranges from 0 to 1.21% (mean: 0.42%) in a twelve year period from 1990 to 2001 (Danish National This review has been accepted as a thesis together with nine previously pub- Registry. Report on Dialysis and Transplantation in Denmark 2001). lished papers by the University of Aarhus, February 5, 2009, and defended on This is probably an underestimate due to the difficulties of establish- May 15, 2009. ing the diagnosis. Department of Clinical Genetics, Aarhus University Hospital, and Faculty of Health Sciences, Aarhus University, Denmark. 1.3 CLINICAL FEATURES OF X-LINKED AS Correspondence: Klinisk Genetisk Afdeling, Århus Sygehus, Århus Univer- 1.3.1 Renal features sitetshospital, Nørrebrogade 44, 8000 Århus C, Denmark. AS in its classic form is a hereditary nephropathy associated with E-mail: [email protected] sensorineural hearing loss and ocular manifestations. The charac- Official opponents: Lisbeth Tranebjærg, Allan Meldgaard Lund, and Torben teristic renal features in AS are persistent microscopic hematuria ap- F.
  • Clinical, Radiological, and Chondro

    Clinical, Radiological, and Chondro

    195 LETTER TO JMG J Med Genet: first published as 10.1136/jmg.40.3.195 on 1 March 2003. Downloaded from Clinical, radiological, and chondro-osseous findings in opsismodysplasia: survey of a series of 12 unreported cases V Cormier-Daire, A L Delezoide, N Philip, P Marcorelles, K Casas, Y Hillion, L Faivre, D L Rimoin, A Munnich, P Maroteaux, M Le Merrer ............................................................................................................................. J Med Genet 2003;40:195–200 psismodysplasia (opsismos in Greek = late) is a rare Key points chondrodysplasia, first described in 1977 by Zonana et al1 as a unique chondrodysplasia and designated O 2 “opsismodysplasia” only in 1984. The disorder is character- • We present the clinical, radiographic, and histological ised clinically by micromelia with extremely short hands and findings of 11 new cases of opsismodysplasia feet and respiratory distress responsible for death in the first belonging to eight families. few years of life.2 The main radiological features include severe • All cases presented with dysmorphic features, large platyspondyly, major delay in skeletal ossification, and anterior fontanelle, short hands and feet, and short stat- metaphyseal cupping. To date, 13 cases have been reported ure. Radiographic features included very delayed bone and recurrence in sibs and/or consanguinity have suggested maturation, marked shortness of the hand and foot an autosomal recessive mode of inheritance.1–6 Here, we bones with metaphyseal cupping and thin vertebral describe the clinical, radiological and chondro-osseous find- bodies. ings of 12 previously unreported cases in nine families. We • The outcome was variable and five children are still show that opsismodysplasia is not a consistently lethal condi- alive.
  • The Ehlers–Danlos Syndromes

    The Ehlers–Danlos Syndromes

    PRIMER The Ehlers–Danlos syndromes Fransiska Malfait1 ✉ , Marco Castori2, Clair A. Francomano3, Cecilia Giunta4, Tomoki Kosho5 and Peter H. Byers6 Abstract | The Ehlers–Danlos syndromes (EDS) are a heterogeneous group of hereditary disorders of connective tissue, with common features including joint hypermobility, soft and hyperextensible skin, abnormal wound healing and easy bruising. Fourteen different types of EDS are recognized, of which the molecular cause is known for 13 types. These types are caused by variants in 20 different genes, the majority of which encode the fibrillar collagen types I, III and V, modifying or processing enzymes for those proteins, and enzymes that can modify glycosaminoglycan chains of proteoglycans. For the hypermobile type of EDS, the molecular underpinnings remain unknown. As connective tissue is ubiquitously distributed throughout the body, manifestations of the different types of EDS are present, to varying degrees, in virtually every organ system. This can make these disorders particularly challenging to diagnose and manage. Management consists of a care team responsible for surveillance of major and organ-specific complications (for example, arterial aneurysm and dissection), integrated physical medicine and rehabilitation. No specific medical or genetic therapies are available for any type of EDS. The Ehlers–Danlos syndromes (EDS) comprise a genet­ six EDS types, denominated by a descriptive name6. The ically heterogeneous group of heritable conditions that most recent classification, the revised EDS classification in share several clinical features, such as soft and hyper­ 2017 (Table 1) identified 13 distinct clinical EDS types that extensible skin, abnormal wound healing, easy bruising are caused by alterations in 19 genes7.
  • SKELETAL DYSPLASIA Dr Vasu Pai

    SKELETAL DYSPLASIA Dr Vasu Pai

    SKELETAL DYSPLASIA Dr Vasu Pai Skeletal dysplasia are the result of a defective growth and development of the skeleton. Dysplastic conditions are suspected on the basis of abnormal stature, disproportion, dysmorphism, or deformity. Diagnosis requires Simple measurement of height and calculation of proportionality [<60 inches: consideration of dysplasia is appropriate] Dysmorphic features of the face, hands, feet or deformity A complete physical examination Radiographs: Extremities and spine, skull, Pelvis, Hand Genetics: the risk of the recurrence of the condition in the family; Family evaluation. Dwarf: Proportional: constitutional or endocrine or malnutrition Disproportion [Trunk: Extremity] a. Height < 42” Diastrophic Dwarfism < 48” Achondroplasia 52” Hypochondroplasia b. Trunk-extremity ratio May have a normal trunk and short limbs (achondroplasia), Short trunk and limbs of normal length (e.g., spondylo-epiphyseal dysplasia tarda) Long trunk and long limbs (e.g., Marfan’s syndrome). c. Limb-segment ratio Normal: Radius-Humerus ratio 75% Tibia-Femur 82% Rhizomelia [short proximal segments as in Achondroplastics] Mesomelia: Dynschondrosteosis] Acromelia [short hands and feet] RUBIN CLASSIFICATION 1. Hypoplastic epiphysis ACHONDROPLASTIC Autosomal Dominant: 80%; 0.5-1.5/10000 births Most common disproportionate dwarfism. Prenatal diagnosis: 18 weeks by measuring femoral and humeral lengths. Abnormal endochondral bone formation: zone of hypertrophy. Gene defect FGFR fibroblast growth factor receptor 3 . chromosome 4 Rhizomelic pattern, with the humerus and femur affected more than the distal extremities; Facies: Frontal bossing; Macrocephaly; Saddle nose Maxillary hypoplasia, Mandibular prognathism Spine: Lumbar lordosis and Thoracolumbar kyphosis Progressive genu varum and coxa valga Wedge shaped gaps between 3rd and 4th fingers (trident hands) Trident hand 50%, joint laxity Pathology Lack of columnation Bony plate from lack of growth Disorganized metaphysis Orthopaedics 1.
  • MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature

    MECHANISMS in ENDOCRINOLOGY: Novel Genetic Causes of Short Stature

    J M Wit and others Genetics of short stature 174:4 R145–R173 Review MECHANISMS IN ENDOCRINOLOGY Novel genetic causes of short stature 1 1 2 2 Jan M Wit , Wilma Oostdijk , Monique Losekoot , Hermine A van Duyvenvoorde , Correspondence Claudia A L Ruivenkamp2 and Sarina G Kant2 should be addressed to J M Wit Departments of 1Paediatrics and 2Clinical Genetics, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, Email The Netherlands [email protected] Abstract The fast technological development, particularly single nucleotide polymorphism array, array-comparative genomic hybridization, and whole exome sequencing, has led to the discovery of many novel genetic causes of growth failure. In this review we discuss a selection of these, according to a diagnostic classification centred on the epiphyseal growth plate. We successively discuss disorders in hormone signalling, paracrine factors, matrix molecules, intracellular pathways, and fundamental cellular processes, followed by chromosomal aberrations including copy number variants (CNVs) and imprinting disorders associated with short stature. Many novel causes of GH deficiency (GHD) as part of combined pituitary hormone deficiency have been uncovered. The most frequent genetic causes of isolated GHD are GH1 and GHRHR defects, but several novel causes have recently been found, such as GHSR, RNPC3, and IFT172 mutations. Besides well-defined causes of GH insensitivity (GHR, STAT5B, IGFALS, IGF1 defects), disorders of NFkB signalling, STAT3 and IGF2 have recently been discovered. Heterozygous IGF1R defects are a relatively frequent cause of prenatal and postnatal growth retardation. TRHA mutations cause a syndromic form of short stature with elevated T3/T4 ratio. Disorders of signalling of various paracrine factors (FGFs, BMPs, WNTs, PTHrP/IHH, and CNP/NPR2) or genetic defects affecting cartilage extracellular matrix usually cause disproportionate short stature.
  • Orphanet Report Series Rare Diseases Collection

    Orphanet Report Series Rare Diseases Collection

    Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic
  • Mackenzie's Mission Gene & Condition List

    Mackenzie's Mission Gene & Condition List

    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
  • Rapid Publication International Nosology and Classification of Constitutional Disorders of Bone

    Rapid Publication International Nosology and Classification of Constitutional Disorders of Bone

    American Journal of Medical Genetics 113:65–77 (2002) Rapid Publication International Nosology and Classification of Constitutional Disorders of Bone (2001) Christine M. Hall* Department of Radiology, Great Ormond Street Children’s Hospital, London, United Kingdom The last International Classification of Con- combination of morphological and molecular groupings stitutional Disorders of Bone was published it is anticipated that two parallel but interacting clas- in 1998. Since then rapid advances have been sifications will evolve: one clinical, identifying accepted made in identifying the molecular changes terminology or nosology, and the other molecular, to responsible for defined conditions and new help further understand the pathogenesis of individual disorders are constantly being delineated. disorders. For these reasons a further update on the The major change in the classification has been the classification is appropriate. It has been addition of genetically determined dysostoses to the expended to not only the osteochondrodys- skeletal dysplasias or osteochondrodysplasias. This is plasias (33 groups) but also genetically deter- because in clinical practice these two groups overlap. mined dysostoses (3 groups). Dysostoses may be defined as skeletal malformations ß 2002 Wiley-Liss, Inc. occurring singly or in combination. The dysostoses are static and their malformations occur during blastogen- KEY WORDS: osteochondrodysplasia; dys- esis (the first eight weeks of embryonic life). This is in ostosis; gene contrast to the skeletal dysplasias which often present after this stage, have a more general skeletal involve- ment and continue to evolve as a result of active gene The International Working Group on the Classifica- involvement throughout life. Only those dysostoses tion of Constitutional Disorders of Bone met in Oxford which have an identified chromosomal locus have been on September 4th and 5th 2001 to update the last clas- included.
  • Coding RNA Genes

    Coding RNA Genes

    Review A guide to naming human non-coding RNA genes Ruth L Seal1,2,* , Ling-Ling Chen3, Sam Griffiths-Jones4, Todd M Lowe5, Michael B Mathews6, Dawn O’Reilly7, Andrew J Pierce8, Peter F Stadler9,10,11,12,13, Igor Ulitsky14 , Sandra L Wolin15 & Elspeth A Bruford1,2 Abstract working on non-coding RNA (ncRNA) nomenclature in the mid- 1980s with the approval of initial gene symbols for mitochondrial Research on non-coding RNA (ncRNA) is a rapidly expanding field. transfer RNA (tRNA) genes. Since then, we have worked closely Providing an official gene symbol and name to ncRNA genes brings with experts in the ncRNA field to develop symbols for many dif- order to otherwise potential chaos as it allows unambiguous ferent kinds of ncRNA genes. communication about each gene. The HUGO Gene Nomenclature The number of genes that the HGNC has named per ncRNA class Committee (HGNC, www.genenames.org) is the only group with is shown in Fig 1, and ranges in number from over 4,500 long the authority to approve symbols for human genes. The HGNC ncRNA (lncRNA) genes and over 1,900 microRNA genes, to just four works with specialist advisors for different classes of ncRNA to genes in the vault and Y RNA classes. Every gene symbol has a ensure that ncRNA nomenclature is accurate and informative, Symbol Report on our website, www.genenames.org, which where possible. Here, we review each major class of ncRNA that is displays the gene symbol, gene name, chromosomal location and currently annotated in the human genome and describe how each also includes links to key resources such as Ensembl (Zerbino et al, class is assigned a standardised nomenclature.
  • Genetic Disorder

    Genetic Disorder

    Genetic disorder Single gene disorder Prevalence of some single gene disorders[citation needed] A single gene disorder is the result of a single mutated gene. Disorder Prevalence (approximate) There are estimated to be over 4000 human diseases caused Autosomal dominant by single gene defects. Single gene disorders can be passed Familial hypercholesterolemia 1 in 500 on to subsequent generations in several ways. Genomic Polycystic kidney disease 1 in 1250 imprinting and uniparental disomy, however, may affect Hereditary spherocytosis 1 in 5,000 inheritance patterns. The divisions between recessive [2] Marfan syndrome 1 in 4,000 and dominant types are not "hard and fast" although the [3] Huntington disease 1 in 15,000 divisions between autosomal and X-linked types are (since Autosomal recessive the latter types are distinguished purely based on 1 in 625 the chromosomal location of Sickle cell anemia the gene). For example, (African Americans) achondroplasia is typically 1 in 2,000 considered a dominant Cystic fibrosis disorder, but children with two (Caucasians) genes for achondroplasia have a severe skeletal disorder that 1 in 3,000 Tay-Sachs disease achondroplasics could be (American Jews) viewed as carriers of. Sickle- cell anemia is also considered a Phenylketonuria 1 in 12,000 recessive condition, but heterozygous carriers have Mucopolysaccharidoses 1 in 25,000 increased immunity to malaria in early childhood, which could Glycogen storage diseases 1 in 50,000 be described as a related [citation needed] dominant condition. Galactosemia
  • Blueprint Genetics Comprehensive Skeletal Dysplasias and Disorders

    Blueprint Genetics Comprehensive Skeletal Dysplasias and Disorders

    Comprehensive Skeletal Dysplasias and Disorders Panel Test code: MA3301 Is a 251 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of disorders involving the skeletal system. About Comprehensive Skeletal Dysplasias and Disorders This panel covers a broad spectrum of skeletal disorders including common and rare skeletal dysplasias (eg. achondroplasia, COL2A1 related dysplasias, diastrophic dysplasia, various types of spondylo-metaphyseal dysplasias), various ciliopathies with skeletal involvement (eg. short rib-polydactylies, asphyxiating thoracic dysplasia dysplasias and Ellis-van Creveld syndrome), various subtypes of osteogenesis imperfecta, campomelic dysplasia, slender bone dysplasias, dysplasias with multiple joint dislocations, chondrodysplasia punctata group of disorders, neonatal osteosclerotic dysplasias, osteopetrosis and related disorders, abnormal mineralization group of disorders (eg hypopohosphatasia), osteolysis group of disorders, disorders with disorganized development of skeletal components, overgrowth syndromes with skeletal involvement, craniosynostosis syndromes, dysostoses with predominant craniofacial involvement, dysostoses with predominant vertebral involvement, patellar dysostoses, brachydactylies, some disorders with limb hypoplasia-reduction defects, ectrodactyly with and without other manifestations, polydactyly-syndactyly-triphalangism group of disorders, and disorders with defects in joint formation and synostoses. Availability 4 weeks Gene Set Description